Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ischemic Heart Disease

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 210 articles: HTML format

Single Articles

October 2026
1. BROYD CJ, Arunothayaraj S, Scheller B, Eccleshall S, et al
   The European bifurcation club randomized trial of stepwise provisional stenting vs drug-coated balloon therapy for nonleft main true coronary bifurcations: The EBC DCB trial.
   Am Heart J. 2026;300:107463.
   PubMed     Abstract available
   
   
   September 2026
2. NAMBA HF, de Jong EAM, Boerhout CKM, Mechroubi A, et al
   Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study.
   Am Heart J. 2026;299:107451.
   PubMed     Abstract available
   
   
   
3. BOCCHINO PP, Ortega-Hernandez JA, Baldetti L, Gallone G, et al
   External validation of organ perfusion pressure as a prognostic marker in cardiogenic shock.
   Am Heart J. 2026;299:107448.
   PubMed     Abstract available
   
   
   July 2026
4. BERTOLET M, Triulzi DJ, Campbell-Lee S, Gordeuk VR, et al
   Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange (SCD-CARRE) trial.
   Am Heart J. 2026 Jul 15:107542. doi: 10.1016/j.ahj.2026.107542.
   PubMed     Abstract available
   
   
   
5. OPOLSKI MP, Spiewak M, Machaj F, Borzuta H, et al
   Antegrade dissection and re-entry versus retrograde strategy in chronic total occlusion percutaneous coronary intervention: Rationale and design of the ADRENALINE randomized study.
   Am Heart J. 2026 Jul 11:107538. doi: 10.1016/j.ahj.2026.107538.
   PubMed     Abstract available
   
   
   
6. GIANNAKOPOULOU SP, Chrysohoou C, Antonopoulou S, Barkas F, et al
   Integrative assessment of high-sensitivity C-reactive protein and lipid levels in predicting 20-year atherosclerotic cardiovascular disease risk, in a Mediterranean population: The ATTICA study (2002-2022).
   Am Heart J. 2026 Jul 11:107540. doi: 10.1016/j.ahj.2026.107540.
   PubMed     Abstract available
   
   
   
7. SCHEIER TC, Gerstein HC, Mosterd A, Qilong Y, et al
   Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: a descriptive compatibility analysis.
   Am Heart J. 2026 Jul 11:107539. doi: 10.1016/j.ahj.2026.107539.
   PubMed     Abstract available
   
   
   
8. ANG D, Young R, Taggart D, Carrick D, et al
   International study of Coronary Microvascular Angina (iCorMicA): a registry-based diagnostic study and nested randomized trial.
   Am Heart J. 2026 Jul 6:107527. doi: 10.1016/j.ahj.2026.107527.
   PubMed     Abstract available
   
   
   
9. SYKES R, Tan D, McKinley G, Carrick D, et al
   Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.
   Am Heart J. 2026 Jul 2:107518. doi: 10.1016/j.ahj.2026.107518.
   PubMed     Abstract available
   
   
   
10. BLOOM JE, Ball J, Okyere D, Voskoboinik A, et al
    Design and rationale of a multicenter paramedic randomized trial of noradrenaline versus adrenaline in the initial management of patients with cardiogenic shock-The PANDA trial.
    Am Heart J. 2026;297:107378.
    PubMed     Abstract available
    
    
    June 2026
11. HOLTZMAN JN, Marcus GM, Seltzer J
    Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.
    Am Heart J. 2026 Jun 27:107522. doi: 10.1016/j.ahj.2026.107522.
    PubMed    
    
    
    
12. PUNDI K, Gandotra C, Sanders W, Senatore F, et al
    Considerations for Using Atrial Fibrillation Burden as a Surrogate Endpoint A Report from the Cardiovascular Sciences Research Consortium.
    Am Heart J. 2026 Jun 22:107516. doi: 10.1016/j.ahj.2026.107516.
    PubMed     Abstract available
    
    
    
13. MURO FMD, Raona V, Sartori S, Smith K, et al
    Prognostic Impact of Combined Inflammatory Markers in Patients Undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2026 Jun 21:107519. doi: 10.1016/j.ahj.2026.107519.
    PubMed     Abstract available
    
    
    
14. ZEDER K, Seltzer J, DeFilippi C
    Brief Communication: Biomarkers as endpoints in cardiovascular clinical trials -Report from the Cardiovascular Sciences Research Consortium.
    Am Heart J. 2026 Jun 18:107511. doi: 10.1016/j.ahj.2026.107511.
    PubMed    
    
    
    
15. LIP GYH, Kuzma L
    Revisiting Direct Oral Anticoagulant Monotherapy Versus Combination Therapy With Antiplatelets In Chronic Coronary Syndrome Patients With Prior Percutaneous Coronary Intervention: Balancing thromboembolism, mortality and bleeding.
    Am Heart J. 2026 Jun 8:107509. doi: 10.1016/j.ahj.2026.107509.
    PubMed    
    
    
    
16. CORTESE B, Mohammed AA, Malakouti S, Sivalingam J, et al
    Antiplatelet treatment after drug-coated balloon treatment: Review of the current evidence and future perspectives.
    Am Heart J. 2026;296:107361.
    PubMed     Abstract available
    
    
    
17. LIAO W, Rashid M, Brookes CL, Barber S, et al
    Study design for an emulated trial of a 2 arm, parallel, stratified, adaptive, RCT of CABG versus PCI in people requiring myocardial revascularization at high risk (High-Risk REVASC).
    Am Heart J. 2026;296:107368.
    PubMed     Abstract available
    
    
    May 2026
18. STEG PG, Goodman SG, Jukema JW, Martens P, et al
    Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.
    Am Heart J. 2026 May 26:107493. doi: 10.1016/j.ahj.2026.107493.
    PubMed     Abstract available
    
    
    
19. CHI KY, Karthikeyan A, Chang Y, Lee PL, et al
    Direct Oral Anticoagulant Monotherapy versus Combination Therapy with Antiplatelets in Chronic Coronary Syndrome Patients with Prior Percutaneous Coronary Intervention Requiring Anticoagulation: A Meta-Analysis.
    Am Heart J. 2026 May 17:107492. doi: 10.1016/j.ahj.2026.107492.
    PubMed     Abstract available
    
    
    
20. KORJIAN S, Gibson CM, Seltzer J, Mahaffey KW, et al
    Cardiovascular Regulatory Science: Accelerating the Path from Bench to Bedside.
    Am Heart J. 2026 May 16:107487. doi: 10.1016/j.ahj.2026.107487.
    PubMed     Abstract available
    
    
    
21. HOSSEINI F, Kang M, Segal T, Singer J, et al
    Impact of Malnutrition on Outcomes among elderly ST-Elevation Myocardial Infarction Patients receiving Primary PCI.
    Am Heart J. 2026 May 15:107489. doi: 10.1016/j.ahj.2026.107489.
    PubMed     Abstract available
    
    
    
22. WANG W, Gu Y, Wang D, Zhang W, et al
    High-Intensity Interval Training Combined with Moderate-Intensity Continuous Training in Post-PCI Acute Myocardial Infarction Patients: A Randomized Controlled Trial.
    Am Heart J. 2026 May 8:107472. doi: 10.1016/j.ahj.2026.107472.
    PubMed     Abstract available
    
    
    
23. ANDERSON JL, May HT, Winslow T, Le VT, et al
    CorCal Outcomes: a Randomized Trial using the Pooled Cohort Equation or Coronary Artery Calcium to Select Statin Therapy in Primary Prevention Patients. Study Design and Baseline Characteristics.
    Am Heart J. 2026 May 7:107473. doi: 10.1016/j.ahj.2026.107473.
    PubMed     Abstract available
    
    
    April 2026
24. WOELDERS ECI, Yosofi B, Peeters DAM, von Birgelen C, et al
    Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction; a randomized pilot study.
    Am Heart J. 2026 Apr 28:107460. doi: 10.1016/j.ahj.2026.107460.
    PubMed     Abstract available
    
    
    
25. JANSSEN S, Luijkx JJP, Swinnen W, Vriesendorp P, et al
    Direct oral anticoagulation interruption versus continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: design and rationale of the South Limburg Myocardial Infarction study group trial 2 (SLIM
    Am Heart J. 2026 Apr 27:107462. doi: 10.1016/j.ahj.2026.107462.
    PubMed     Abstract available
    
    
    
26. LIU OC, Billings J, Katz JN, Rao SV, et al
    Association Between Hospital Ownership Type and ST-Segment Elevation Myocardial Infarction Outcomes: Insights from the National Readmission Database, 2016-2022.
    Am Heart J. 2026 Apr 23:107452. doi: 10.1016/j.ahj.2026.107452.
    PubMed     Abstract available
    
    
    
27. SUSCHA C, Luterstein E, Tong N, Murphy S, et al
    Validity of international classification of diseases, tenth revision codes in diagnosing myocardial infarction subtypes.
    Am Heart J. 2026 Apr 19:107447. doi: 10.1016/j.ahj.2026.107447.
    PubMed     Abstract available
    
    
    
28. ZHAO J, Hong H, Fanaroff A, Zhong S, et al
    Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry.
    Am Heart J. 2026 Apr 14:107445. doi: 10.1016/j.ahj.2026.107445.
    PubMed     Abstract available
    
    
    
29. LAVI S, Shadpour S, Allen E, Ogunsakin RE, et al
    Design and rational of the The PRACTICAL-HERO trial: a randomized trial of higher and lower doses of heparin vs placebo for elective diagnostic coronary angiography.
    Am Heart J. 2026 Apr 13:107441. doi: 10.1016/j.ahj.2026.107441.
    PubMed     Abstract available
    
    
    
30. HOES LLF, Geleijnse JM, Bemelmans RHH, Muller AF, et al
    An online, Predominantly Plant-based, Dietary Intervention for Improving Cardiovascular Risk: a Randomized Controlled Trial in People with Type 2 Diabetes.
    Am Heart J. 2026 Apr 2:107436. doi: 10.1016/j.ahj.2026.107436.
    PubMed     Abstract available
    
    
    
31. BORGES DO NASCIMENTO IJ, Lopes RD, Malveira De Lima MV, Itaborahy MF, et al
    Coevolutionary analysis of evidence and recommendations in STEMI clinical practice guidelines: A 33-year meta-research study of ACC, AHA, and ESC.
    Am Heart J. 2026;294:107326.
    PubMed     Abstract available
    
    
    
32. BOLLI R, Tang XL, Hare JM, Mitrani RD, et al
    Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy.
    Am Heart J. 2026;294:107328.
    PubMed     Abstract available
    
    
    
33. JIN IT, Lee SH, Yun KH, Kim W, et al
    Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial.
    Am Heart J. 2026 Apr 1:107437. doi: 10.1016/j.ahj.2026.107437.
    PubMed     Abstract available
    
    
    March 2026
34. GOLDSTEIN DJ, Reichenspurner H, Vorovich E, Teuteberg J, et al
    Design and Rationale of the Impella(R)-Protected Cardiac Surgery Trial (IMPACT): A Multicenter, Single-arm Pilot Study in High-Risk Cardiac Surgery Patients.
    Am Heart J. 2026 Mar 25:107434. doi: 10.1016/j.ahj.2026.107434.
    PubMed     Abstract available
    
    
    
35. TZOUMAS A, Tapp DN, Ashokprabu N, Schmidt CW, et al
    Enhancing Invasive Coronary Function Testing: Multivessel Assessment of Coronary Microvascular Dysfunction in Patients with Angina and No Obstructive Coronary Artery Disease (ANOCA).
    Am Heart J. 2026 Mar 21:107429. doi: 10.1016/j.ahj.2026.107429.
    PubMed     Abstract available
    
    
    
36. IRIBARREN C, Lu M, Go AS, Rana JS, et al
    Attaining LDL-cholesterol target post major coronary event: Care gap, associated factors and clinical outcomes.
    Am Heart J. 2026 Mar 21:107430. doi: 10.1016/j.ahj.2026.107430.
    PubMed     Abstract available
    
    
    
37. POLETTI E, Thotakura S, Kearney KE, Lombardi WL, et al
    Comparative Validation of Risk Scores for In-Hospital Complications Following Chronic Total Occlusion Percutaneous Coronary Intervention.
    Am Heart J. 2026 Mar 19:107427. doi: 10.1016/j.ahj.2026.107427.
    PubMed     Abstract available
    
    
    
38. TORRES J, Navarro S, Gao H, Xiong T, et al
    American Heart Association cardiovascular health metrics and cancer outcomes: a systematic review and meta-analysis.
    Am Heart J. 2026 Mar 17:107426. doi: 10.1016/j.ahj.2026.107426.
    PubMed     Abstract available
    
    
    
39. IGLESIAS JF, Roffi M, Heg D, Muller O, et al
    IMPACT OF TOTAL STENT LENGTH ON LONG-TERM OUTCOMES WITH DIFFERENT NEWER-GENERATION DRUG-ELUTING STENT DESIGNS IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A SUBGROUP ANALYSIS FROM THE BIOSTEMI ES RANDOMIZED TRIAL.
    Am Heart J. 2026 Mar 9:107421. doi: 10.1016/j.ahj.2026.107421.
    PubMed     Abstract available
    
    
    
40. BIANCHINI E, Alsubai SE, Alqahtani F, Sgreva S, et al
    Characterization of Biomarker Profiles in Patients with Coronary Artery Disease: A Prospective Coronary Computed Tomography Angiography Study.
    Am Heart J. 2026 Mar 7:107423. doi: 10.1016/j.ahj.2026.107423.
    PubMed     Abstract available
    
    
    
41. SIMKEVICH M, Chen YY, Parent M, Patel Y, et al
    Systemic inflammation, myocardial fibrosis, and subclinical cardiovascular disease in people living with HIV.
    Am Heart J. 2026 Mar 4:107399. doi: 10.1016/j.ahj.2026.107399.
    PubMed     Abstract available
    
    
    
42. SENMAN B, Sinha SS, Truesdell AG, Safiriyu I, et al
    Towards an understanding of best practice: The good, the bad and the future of cardiogenic shock teams.
    Am Heart J. 2026;293:107310.
    PubMed     Abstract available
    
    
    
43. PIVATO CA, Mincione G, Gramss L, Pacchioni A, et al
    Early oral anticoagulation monotherapy after PCI: Insights from the POEM trial.
    Am Heart J. 2026;293:107309.
    PubMed     Abstract available
    
    
    February 2026
44. DURSTENFELD MS, Levkova-Clark M, Ms DL, Schaffer V, et al
    Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial.
    Am Heart J. 2026 Feb 28:107400. doi: 10.1016/j.ahj.2026.107400.
    PubMed     Abstract available
    
    
    
45. GOLDSWEIG AM, Ballantyne CM, White HD, Abbott JD, et al
    Effect of Age on Restrictive and Liberal Transfusion Outcomes in Patients with Anemia and Myocardial Infarction.
    Am Heart J. 2026 Feb 19:107381. doi: 10.1016/j.ahj.2026.107381.
    PubMed     Abstract available
    
    
    
46. HERBERT BM, Carson JL, Bertolet M, Alexander JH, et al
    A Comprehensive Set of Per-Protocol Analyses of the Myocardial Ischemia and Transfusion (MINT) Trial.
    Am Heart J. 2026 Feb 18:107382. doi: 10.1016/j.ahj.2026.107382.
    PubMed     Abstract available
    
    
    
47. HEUTS S, Pustjens TFS, Lux A, Gabrio A, et al
    Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI: a Bayesian re-analysis of the SLIM trial.
    Am Heart J. 2026 Feb 5:107369. doi: 10.1016/j.ahj.2026.107369.
    PubMed     Abstract available
    
    
    
48. HESS PL, Fu Z, Desai NR, Alam M, et al
    Associations Between Practice-Level Compliance with Cardiac Performance Measures and Clinical Outcomes in US Cardiovascular Ambulatory Care.
    Am Heart J. 2026 Feb 2:107364. doi: 10.1016/j.ahj.2026.107364.
    PubMed    
    
    
    
49. GIROLAMO O, Ismail MD, Tavella R, Ooi EL, et al
    Functional coronary angiogram findings in angina with non-obstructive coronary arteries patients with coronary slow flow.
    Am Heart J. 2026;292:107287.
    PubMed     Abstract available
    
    
    
50. YOSHIDA Y, Zu Y, Aguilar D, Ferdinand KC, et al
    Cumulative effect of hyperglycemia and insulin resistance on cardiac dysfunction: The coronary artery risk development in young adults (CARDIA) study.
    Am Heart J. 2026;292:107276.
    PubMed     Abstract available
    
    
    
51. FUR CB, Olsen NT, Lassen JF, Eftekhari A, et al
    Design and rationale of aspirin versus aspirin and fondaparinux prior to early invasive strategy in patients with NSTEMI: The FOXY trial.
    Am Heart J. 2026;292:107274.
    PubMed     Abstract available
    
    
    January 2026
52. ARMSTRONG PW, Zheng Y, Welsh RC, Sinnaeve PR, et al
    Primary Percutaneous Coronary Intervention within the First Hour: Insights from Early-Treated Patients with ST-Elevation Myocardial Infarction.
    Am Heart J. 2026 Jan 29:107363. doi: 10.1016/j.ahj.2026.107363.
    PubMed     Abstract available
    
    
    
53. CHANG LS, Hassan S, Chasse J, Stern G, et al
    Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.
    Am Heart J. 2026 Jan 27:107359. doi: 10.1016/j.ahj.2026.107359.
    PubMed     Abstract available
    
    
    
54. FARIDI KF, Quispe R, Martin SS, Jones SR, et al
    Low Levels of Atherogenic Lipoproteins & Incident Atherosclerotic Cardiovascular Disease: A Pooled Cohort Primary Prevention Study.
    Am Heart J. 2026 Jan 27:107354. doi: 10.1016/j.ahj.2026.107354.
    PubMed     Abstract available
    
    
    
55. CHEN X, Li S, Wang B, Chen G, et al
    Staged interventional strategies for acute ST-segment elevation myocardial infarction patient with multi-vessel disease: Rationale and design of a multicenter, randomized STAGED trial.
    Am Heart J. 2026 Jan 13:107352. doi: 10.1016/j.ahj.2026.107352.
    PubMed     Abstract available
    
    
    
56. NACHNANI E, Goel K, Sullivan AE
    Comparative Performance of Large Language Models on Cardiovascular Certification Simulation Exam.
    Am Heart J. 2026 Jan 12:107353. doi: 10.1016/j.ahj.2026.107353.
    PubMed     Abstract available
    
    
    
57. DILETTI R, Daemen J, Faurie B, Barbierato M, et al
    Intravascular Ultrasound Guidance for Complex High-Risk Indicated Procedures: the IVUS CHIP Trial study design.
    Am Heart J. 2026 Jan 3:107339. doi: 10.1016/j.ahj.2026.107339.
    PubMed     Abstract available
    
    
    
58. TAMARAPPOO B, Wolny R, Tomasino GF, Berman D, et al
    Design and Rationale of the WARRIOR Ancillary Study for Coronary CT Angiographic Analysis.
    Am Heart J. 2026 Jan 2:107340. doi: 10.1016/j.ahj.2026.107340.
    PubMed     Abstract available
    
    
    
59. TSIGKAS G, Trigka-Vasilakopoulou A, Apostolos A, Papafaklis M, et al
    Distal versus conventional transradial artery access for coronary catheterization in patients with STEMI (DR-STEMI): Rationale and design of an international, multicenter, randomized trial.
    Am Heart J. 2026;291:73-80.
    PubMed     Abstract available
    
    
    
60. GOLD M, Kulkarni S, Quyyumi A
    Response to letter by Hu regarding article, "Statistical Methodological Limitations and Improvement Suggestions in the Study of Vitamin D Deficiency and Cardiovascular Mortality After Heart Transplantation.".
    Am Heart J. 2026;291:218-219.
    PubMed    
    
    
    
61. HU H, Wang L
    Statistical methodological limitations and improvement suggestions in the study of vitamin D deficiency and cardiovascular mortality after heart transplantation.
    Am Heart J. 2026;291:216-217.
    PubMed    
    
    
    December 2025
62. D'ENTREMONT MA, Lee SF, Wijeysundera HC, Tsang MB, et al
    Design and Rationale of the HD PCI Trial: A Cluster Randomized Crossover Trial of Higher vs. Lower Dose Heparin for Elective Percutaneous Coronary Intervention.
    Am Heart J. 2025 Dec 22:107330. doi: 10.1016/j.ahj.2025.107330.
    PubMed     Abstract available
    
    
    
63. SORGAARD MH, Kristensen AT, Eskesen K, Kofoed KF, et al
    Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography for Interventional Triage in Acute Coronary Syndrome - Design of the Randomized TRACTION Trial.
    Am Heart J. 2025 Dec 6:107325. doi: 10.1016/j.ahj.2025.107325.
    PubMed     Abstract available
    
    
    
64. MCCARTHY CP, Ballantyne CM, Blankstein R, Budoff MJ, et al
    Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics.
    Am Heart J. 2025;290:325-338.
    PubMed     Abstract available
    
    
    
65. VAN DER LANDE ACMH, Diederiks NM, de Koning ER, Bosch J, et al
    Design and rationale of the HARTc 2.0 trial: A multicenter randomized controlled study on the impact of point-of-care high-sensitivity cardiac troponin-I testing in prehospital acute coronary syndrome triage on diagnosis and cost-effectiveness.
    Am Heart J. 2025;290:359-370.
    PubMed     Abstract available
    
    
    November 2025
66. LINGAMSETTY SSP, Medarametla RVSK, Prajapati K, Jitta SR, et al
    Effects of Supersaturated Oxygen Therapy on Infarct Size and Microvascular Obstruction Following Myocardial Infarction: A Systematic Review and Meta-Analysis.
    Am Heart J. 2025 Nov 24:107311. doi: 10.1016/j.ahj.2025.107311.
    PubMed     Abstract available
    
    
    
67. LI J, Wang ZY, Yan J, Li WH, et al
    Prospective, multicenter, randomized controlled study on the efficacy and safety of intravascular ultrasound-guided drug-coated balloon for de novo small-vessel coronary lesions: Design and rationale of the DCB-IVUS trial.
    Am Heart J. 2025 Nov 18:107307. doi: 10.1016/j.ahj.2025.107307.
    PubMed     Abstract available
    
    
    
68. MONTALESCOT G, Bolognese L, Bartus S, Cequier-Fillat A, et al
    Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: Design of the AMUNDSEN Trial.
    Am Heart J. 2025 Nov 3:107295. doi: 10.1016/j.ahj.2025.107295.
    PubMed     Abstract available
    
    
    
69. MAHMOUDI M, Nicholas Z, Jabbour RJ, Shambrook J, et al
    Anatomical, physiological and inflammatory characterization of non-culprit vessels in patients undergoing primary PCI for ST-elevation myocardial infarction in the presence of multivessel disease: Rationale and design of the PICNIC study.
    Am Heart J. 2025 Nov 3:107298. doi: 10.1016/j.ahj.2025.107298.
    PubMed     Abstract available
    
    
    
70. SWOBODA PP, Berry C, McCann GP, Kelion A, et al
    Design and rationale of "a pragmatic approach to the investigation of stable chest pain: A UK, multicenter, randomized trial to assess patient outcomes, quality of life and cost effectiveness (CE-MARC 3)".
    Am Heart J. 2025;289:95-104.
    PubMed     Abstract available
    
    
    October 2025
71. BOEDDINGHAUS J, Bima P, Crisanti L, Keller DI, et al
    PRospective Evaluation of the European Society of Cardiology 0/1h-algorithm;s Safety and Efficacy for Triage of Patients with Suspected Myocardial Infarction (PRESC1SE-MI): Rationale and design of a prospective international multicenter stepped-wedge
    Am Heart J. 2025 Oct 31:107299. doi: 10.1016/j.ahj.2025.107299.
    PubMed     Abstract available
    
    
    
72. IGLESIAS JF, Leibundgut G, Heg D, Gasparini GL, et al
    Distal versus conventional radial large-bore access for percutaneous coronary intervention of complex coronary lesions: Rationale and design of the DISCO COMPLEX randomized superiority trial.
    Am Heart J. 2025 Oct 18:107291. doi: 10.1016/j.ahj.2025.107291.
    PubMed     Abstract available
    
    
    
73. ABDELAZIZ A, Ramadan S, Hasan MT, Desouky M, et al
    Complete Revascularization in Patients with Acute Myocardial Infarction and Multivessel Disease: Pooled Analysis of Kaplan-Meier-Derived Individual-Patient-Data.
    Am Heart J. 2025 Oct 2:107284. doi: 10.1016/j.ahj.2025.107284.
    PubMed     Abstract available
    
    
    
74. LEOSDOTTIR M, Dahlbom L, Back M, Wallentin L, et al
    Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracy.
    Am Heart J. 2025;288:149-158.
    PubMed     Abstract available
    
    
    September 2025
75. LERMAN JB, Koeberl DD, Epstein S, Roessig L, et al
    Developing Therapeutics for Rare Cardiovascular Diseases.
    Am Heart J. 2025 Sep 12:S0002-8703(25)00325-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
76. DE ROJAS JP, Toledo E, Estruch R, Guasch-Ferre M, et al
    Extra-Virgin Olive Oil and Additional Cardiovascular Outcomes in the PREDIMED Trial: An Outcome-Wide Perspective.
    Am Heart J. 2025 Sep 2:S0002-8703(25)00321-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
77. FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al
    Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
    Am Heart J. 2025;287:94-106.
    PubMed     Abstract available
    
    
    August 2025
78. DAGRES N, Gale CP, Nadarajah R, Boveda S, et al
    PRevention Of sudden cardiac death aFter myocardial Infarction by Defibrillator im-plantation: Design and Rationale of the PROFID EHRA randomised clinical trial.
    Am Heart J. 2025 Aug 5:S0002-8703(25)00289-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
79. REVAIAH PC, Serruys PW, Onuma Y, Andreini D, et al
    Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - The VICTO
    Am Heart J. 2025 Aug 4:S0002-8703(25)00291-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
80. SARMA D, Smith R, Padkins M, Rali AS, et al
    Association between vasopressin administration and mortality in patients with cardiogenic shock.
    Am Heart J. 2025;286:88-96.
    PubMed     Abstract available
    
    
    
81. DANDAMUDI K, Lawson BD, Barrett JC, Trankle CR, et al
    Trends of women in cardiovascular disease fellowships 2013-2022.
    Am Heart J. 2025;286:111-115.
    PubMed     Abstract available
    
    
    July 2025
82. REINSTADLER SJ, Kronbichler A, Reindl M, Tiller C, et al
    Selective C-reactive protein apheresis in ST-elevation myocardial infarction: Design and rationale of the randomized CRP-STEMI trial.
    Am Heart J. 2025 Jul 28:S0002-8703(25)00283-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
83. HAN M, Kang J, Kim B, Hwang D, et al
    The impact of body mass index (BMI) on antiplatelet monotherapy strategy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial.
    Am Heart J. 2025 Jul 5:S0002-8703(25)00214-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
84. ADAMS KN, Dickert NW, Stone GW, Facemire C, et al
    EARLY SUPPORT IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION COMPLICATED BY SHOCK. DESIGN OF EXCEPTION FROM INFORMED CONSENT PROCESSES IN RECOVER IV TRIAL.
    Am Heart J. 2025 Jul 2:S0002-8703(25)00204-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
85. MAKUVIRE TT, Latif Z, Atwater S, Shah MK, et al
    Health Care Access and Risk Factor Control in US adults with Cardiovascular Disease from 2015 to 2023.
    Am Heart J. 2025 Jul 2:S0002-8703(25)00208-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
86. KHAN E, Lambrakis K, Briffa T, Cullen LA, et al
    Re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting research evidence to practice using artificial intelligence. (RAPIDx AI)-a cluster randomized study design.
    Am Heart J. 2025;285:106-118.
    PubMed     Abstract available
    
    
    
87. DURAN AT, Barbecho JM, Shaw K, Ye S, et al
    Implementing depression treatment for cardiac populations in rapidly changing contexts: Design of the hybrid effectiveness-implementation IHEART DEPCARE trial.
    Am Heart J. 2025;285:52-65.
    PubMed     Abstract available
    
    
    
88. PITARO N, Nicolas J, Sartori S, Shneyderman M, et al
    Impact of Left Ventricular Function on Outcomes in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2025 Jul 1:S0002-8703(25)00203-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    June 2025
89. SHUKLA J, Schmidt C, Larson D, Murthy A, et al
    Clinical Outcomes and Discharge Disposition in Nonagenarians with ST-Elevation Myocardial Infarction.
    Am Heart J. 2025 Jun 27:S0002-8703(25)00202-9. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
90. HANIF M, Khan LA, Kulkarni A, Bhatia HS, et al
    Global lipoprotein (a) testing trends from 2015 to 2023.
    Am Heart J. 2025 Jun 21:S0002-8703(25)00199-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
91. BHATT AS, Go AS, Parikh RV, Ballance Z, et al
    Electronically Delivered, Cardiovascular-Focused Messaging to Improve Influenza Vaccination: Rationale, Design, and Baseline Characteristics of the KP-VACCINATE Megatrial.
    Am Heart J. 2025 Jun 18:S0002-8703(25)00196-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
92. HOPPER I, Marwick TH, Wolfe R, Amerena J, et al
    STAREE-HEART: a randomized placebo-controlled trial of atorvastatin effects on a marker of cardiac aging in older individuals without prior cardiovascular disease events: Protocol and baseline description of participants.
    Am Heart J. 2025 Jun 12:S0002-8703(25)00193-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
93. CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al
    Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design.
    Am Heart J. 2025;284:11-19.
    PubMed     Abstract available
    
    
    May 2025
94. GENG Q, Ying Z, Zhenyan M, Renqiang Y, et al
    Long-term Prognostic Role of Persistent Microvascular Obstruction Determined by Cardiac Magnetic Resonance for ST-segment Elevation Myocardial Infarction.
    Am Heart J. 2025 May 29:S0002-8703(25)00187-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
95. MAINI AS, Abu-Much A, Redfors B, Wollmuth JR, et al
    Outcomes Among Patients with Coronary Bifurcation Lesions Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention.
    Am Heart J. 2025 May 22:S0002-8703(25)00176-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
96. WHITE HD, O'Brien SM, Boden WE, Fremes SE, et al
    Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention and Associated Outcomes in the ISCHEMIA Trial.
    Am Heart J. 2025 May 20:S0002-8703(25)00165-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
97. GOLD ME, Kulkarni S, Yadalam A, Patel KJ, et al
    Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D Deficiency and Cardiovascular Mortality Following Heart Transplantation.
    Am Heart J. 2025 May 16:S0002-8703(25)00166-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
98. RAI B, Yildiz M, Bergstedt S, Bandari A, et al
    Diversity of Electrocardiographic Patterns in Left Main Culprit Acute ST-Elevation Myocardial Infarction.
    Am Heart J. 2025 May 14:S0002-8703(25)00164-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
99. MESSINGER MC, Ashburn NP, Chait JS, Snavely AC, et al
    Risk of delayed percutaneous coronary intervention for STEMI in the Southeast United States.
    Am Heart J. 2025 May 13:S0002-8703(25)00157-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
100. CARULLI E, McGarvey M, Chabok M, Panoulas V, et al
     Corrigendum to ;;Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study''. [Am Heart J. 2025:282:40-50].
     Am Heart J. 2025;288:89.
     PubMed    
     
     
     
101. JAMES S, Christoffersen AD, David JP, Hacker M, et al
     Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
     Am Heart J. 2025 May 7:S0002-8703(25)00156-5. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
102. KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al
     Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.
     Am Heart J. 2025;283:26-36.
     PubMed     Abstract available
     
     
     April 2025
103. BERGER JS, Lyu C, Iturrate E, Westerhoff M, et al
     Opportunistic Assessment of Abdominal Aortic Calcification using Artificial Intelligence (AI) Predicts Coronary Artery Disease and Cardiovascular Events.
     Am Heart J. 2025 Apr 24:S0002-8703(25)00137-1. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
104. SOH CH, Chen J, Marwick TH
     Incidence Rate of Coronary Atherosclerosis among Cancer Types during Survivorship: A Systematic Review and Meta-Analysis.
     Am Heart J. 2025 Apr 23:S0002-8703(25)00142-5. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
105. CROOIJMANS C, Jansen T, van de Hoef TP, Paradies V, et al
     Design and rationale of the efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS).
     Am Heart J. 2025 Apr 22:S0002-8703(25)00138-3. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
106. DILLINGER JG, Pezel T, Batias L, Angoulvant D, et al
     Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trial.
     Am Heart J. 2025 Apr 21:S0002-8703(25)00132-2. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
107. LI L, Sun H, Jin Z, Li J, et al
     Positive outcome trials driven by reduction in nonfatal myocardial infarction: A systematic review and relevant guideline recommendations.
     Am Heart J. 2025 Apr 18:S0002-8703(25)00136-X. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
108. HAKEEM A, Ali Shah J, Kumar R, Khan K, et al
     Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.
     Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
109. NATHAN A
     Response to letter by Ferguson regarding article, "Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.".
     Am Heart J. 2025 Apr 10:S0002-8703(25)00126-7. doi: 10.1016/j.ahj.2025.
     PubMed    
     
     
     
110. FERGUSON M
     Letter by Ferguson regarding article, "Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.".
     Am Heart J. 2025 Apr 9:S0002-8703(25)00125-5. doi: 10.1016/j.ahj.2025.
     PubMed    
     
     
     
111. SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al
     Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.
     Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
112. KULASINGAM A, Laustsen S, Busk M, Sand NP, et al
     Rationale and Design of VICAD-RISK study: Visualization of Coronary Artery Disease for Modification of Risk Factors.
     Am Heart J. 2025 Apr 3:S0002-8703(25)00107-3. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
113. PINCOMBE A, Gray J, Hickling S, Sanfilippo F, et al
     Cost-effectiveness of the transition from Conventional to High-Sensitivity Troponin Assay for the Investigation and Management of Suspected Acute Coronary Syndrome in the Emergency Department.
     Am Heart J. 2025 Apr 2:S0002-8703(25)00104-8. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
114. CHO L, Nicholls SJ, Nordestgaard BG, Landmesser U, et al
     Design and rationale of Lp(a)HORIZON trial: Assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a).
     Am Heart J. 2025 Apr 2:S0002-8703(25)00101-2. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     March 2025
115. HOFMANN R, James S, Sundqvist MO, Warme J, et al
     HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute Myocardial Infarction(HELP-MI SWEDEHEART)Design and rationale of a cluster randomized, crossover, registry-based clinical trial.
     Am Heart J. 2025 Mar 27:S0002-8703(25)00096-1. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
116. NOORY N, Westin O, Borgersen EH, Kragelund C, et al
     Absence of Coronary Artery Disease in Patients Undergoing Coronary Imaging and Association with Amyloidosis - A Danish Nationwide Study.
     Am Heart J. 2025 Mar 26:S0002-8703(25)00093-6. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
117. ZEYMER U, Hassinger F, Bramlage P, Schafer A, et al
     Hyperoxemic Oxygen Therapy in Patients with Acute Anterior Myocardial Infarction: HOT-AAMI - Design and Rationale of a Randomized Trial.
     Am Heart J. 2025 Mar 21:S0002-8703(25)00095-X. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
118. OSUDE N, Spall HV, Bosworth H, Krychtiuk K, et al
     Advancement of the Implementation of Evidence-based Therapies for Cardiovascular-Kidney-Metabolic Conditions: A Multi-Stakeholder Perspective.
     Am Heart J. 2025 Mar 17:S0002-8703(25)00084-5. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
119. ONUMA Y, Ninomiya K, Sjauw K, Damman P, et al
     Accuracy of Instantaneous Wave-free Ratio and Fractional Flow Reserve Derived From Single Coronary Angiographic Projections.
     Am Heart J. 2025 Mar 11:S0002-8703(25)00071-7. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
120. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
     Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial.
     Am Heart J. 2025 Mar 11:S0002-8703(25)00072-9. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
121. YU J, Indraratna P, Briggs NE, Brown P, et al
     Rationale and design of the TeleClinical Care (TCC) -Cardiac trial: A pragmatic randomized trial of adjunctive virtual models of care in the secondary prevention of cardiovascular events.
     Am Heart J. 2025 Mar 11:S0002-8703(25)00091-2. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
122. SERPA F, Perera S, Cruz D, Figueroa JF, et al
     Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Hispanic or Latino Adults in the United States.
     Am Heart J. 2025 Mar 9:S0002-8703(25)00070-5. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
123. LAI Y, Zhang S, Guo Y, Xu C, et al
     Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk.
     Am Heart J. 2025;281:157-167.
     PubMed     Abstract available
     
     
     
124. PATEL S, Fung M, Prasai S, Butalia S, et al
     Emergency department visits and hospitalizations after a diagnosis of angina with no obstructive coronary artery disease (ANOCA).
     Am Heart J. 2025 Mar 1:S0002-8703(25)00067-5. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     February 2025
125. AUER J, Lamm G
     High-risk features and probability of ischemic and bleeding events after percutaneous coronary intervention.
     Am Heart J. 2025 Feb 26:S0002-8703(25)00058-4. doi: 10.1016/j.ahj.2025.
     PubMed    
     
     
     
126. JACOBSEN MR, Jabbari R, Grove EL, Maeng M, et al
     Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT.
     Am Heart J. 2025 Feb 25:S0002-8703(25)00059-6. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
127. TAKAHASHI T, Wei J, Iribarren AC, Gulati M, et al
     Rationale and design of the Women's Ischemia Syndrome Evaluation Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (WISE Pre-HFpEF).
     Am Heart J. 2025 Feb 24:S0002-8703(25)00056-0. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
128. HAFF N, Horn DM, Bhatkhande G, Sung M, et al
     Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
     Am Heart J. 2025 Feb 20:S0002-8703(25)00038-9. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
129. GIBSON CM, Bahit MC, Mehran R, Mehta SR, et al
     Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS).
     Am Heart J. 2025 Feb 20:S0002-8703(25)00044-4. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
130. ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al
     Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial: Functional coronary angiography in STEMI patients.
     Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
131. LEENING MJG, Khan CF, Zhu F, Singh SS, et al
     Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification.
     Am Heart J. 2025 Feb 18:S0002-8703(25)00040-7. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
132. TIAN Y, Wang X, Hu Z, Yu X, et al
     Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study).
     Am Heart J. 2025 Feb 13:S0002-8703(25)00035-3. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
133. BAINEY KR, Welsh RC, Zheng Y, Arias-Mendoza A, et al
     Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2.
     Am Heart J. 2025 Feb 12:S0002-8703(25)00032-8. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
134. GAO XF, Kan J, Wu HY, Chen J, et al
     Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
     Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
135. WANG G, Zhang R, Chen SL, Wang J, et al
     Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO Non-Inferiority Randomized Trial.
     Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
136. MACHLINE-CARRION MJ, Girotto AN, Raupp P, Marton Pereira P, et al
     Rationale, design and pre-randomization data for a cluster randomized trial to assess the effect of a digitally enabled quality improvement intervention on LDL-C control in established atherosclerotic cardiovascular disease patients: The SAPPHIRE-LDL
     Am Heart J. 2025 Feb 3:S0002-8703(25)00020-1. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     January 2025
137. STEG PG, Nicolas J, Baber U, Sartori S, et al
     Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial.
     Am Heart J. 2025 Jan 29:S0002-8703(25)00016-X. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
138. EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al
     Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary intervention. Rationale and s
     Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
139. EBRAHIMI M, Fonarow GC
     Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A Landscape Beyond Diabetes and Prediabetes.
     Am Heart J. 2025 Jan 23:S0002-8703(25)00008-0. doi: 10.1016/j.ahj.2025.
     PubMed    
     
     
     
140. PORTELA GT, Ducrocq G, Bertolet M, Alexander JH, et al
     Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia.
     Am Heart J. 2025 Jan 16:S0002-8703(25)00009-2. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
141. POLOMSKI EAS, Heemelaar JC, de Ronde MES, Al Jaff AAM, et al
     Increased Prevalence of Coronary Atherosclerosis in Cancer Survivors: A Retrospective Matched Cross-sectional Study with Coronary CT Angiography.
     Am Heart J. 2025 Jan 8:S0002-8703(25)00004-3. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
142. BRIX GS, Rasmussen LD, Rohde PD, Nissen L, et al
     Elevated lipoprotein(a) is independently associated with the presence of significant coronary stenosis in de-novo patients with stable chest pain.
     Am Heart J. 2025 Jan 7:S0002-8703(25)00001-8. doi: 10.1016/j.ahj.2025.
     PubMed     Abstract available
     
     
     
143. VAN STEENWIJK MPJ, van Rosmalen J, Elzo Kraemer CV, Donker DW, et al
     A randomized embedded multifactorial adaptive platform for extra corporeal membrane oxygenation (REMAP ECMO) - design and rationale of the left ventricular unloading trial domain.
     Am Heart J. 2025;279:81-93.
     PubMed     Abstract available
     
     
     December 2024
144. CARULLI E, McGarvey M, Chabok M, Panoulas V, et al
     Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study.
     Am Heart J. 2024 Dec 30:S0002-8703(24)00338-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
145. BURGESS S, Zaman S, Towns C, Coylewright M, et al
     The under-representation of women in cardiovascular clinical trials: State-of-the-art review and ethical considerations.
     Am Heart J. 2024 Dec 27:S0002-8703(24)00340-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
146. NELSON AJ, Kaltenbach LA, McGuire DK, Levya M, et al
     Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
     Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
147. XU L, Xu H, Wu S, Zhang H, et al
     Indobufen-based Dual Antiplatelet Therapy in Patients with Multivessel Coronary Disease Undergoing Drug-eluting Stent Implantation Insight From the OPTION Trial.
     Am Heart J. 2024 Dec 20:S0002-8703(24)00335-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
148. CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al
     Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
     Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
149. POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al
     Hospital-level variation in cardiac rehabilitation metrics.
     Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
150. KAUL P, Barrett O, Savu A, Liyanage V, et al
     Association between adverse birth outcomes and long-term risk of premature cardiovascular disease and mortality in a contemporary population-based cohort of 502,383 pregnant women.
     Am Heart J. 2024 Dec 12:S0002-8703(24)00331-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
151. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
     Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
     Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
152. IKEMURA N, Chan PS, Gosch K, Nguyen DD, et al
     Health Status Outcomes after Acute Myocardial Infarction in Patients without Standard Modifiable Risk Factors.
     Am Heart J. 2024 Dec 3:S0002-8703(24)00317-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
153. REDDY KP, Shutlz K, Eberly LA, Khatana SAM, et al
     Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.
     Am Heart J. 2024 Dec 2:S0002-8703(24)00305-3. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
154. BUDGEON CA, Nidorf S, Mosterd A, Fiolet A, et al
     Exploration of the regional effects of colchicine in the LoDoCo2 trial.
     Am Heart J. 2024;278:186-194.
     PubMed     Abstract available
     
     
     
155. KHAND A, Hatherley J, Dakshi A, Miller G, et al
     Safety and feasibility of triage and rapid discharge of patients with chest pain from emergency room: A pragmatic, randomized noninferiority control trial of the European Society of Cardiology (ESC) 0 to 1 hour pathway vs conventional 0 to 3 hour acce
     Am Heart J. 2024;278:235-247.
     PubMed     Abstract available
     
     
     November 2024
156. ARAIZA-GARAYGORDOBIL D, Gopar-Nieto R, Sierra-Lara Martinez JD, S Ajit M, et al
     A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia.
     Am Heart J. 2024 Nov 28:S0002-8703(24)00304-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
157. FANAROFF AC, Vora AN, Wojdyla DM, Mehran R, et al
     Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.
     Am Heart J. 2024 Nov 16:S0002-8703(24)00297-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
158. ENGEL-REBITZER E, Marinacci L, Zheng Z, Wadhera RK, et al
     Changes in coverage, access, and health status among adults with cardiovascular disease after medicaid work requirements.
     Am Heart J. 2024 Nov 14:S0002-8703(24)00276-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
159. NOORY N, Westin O, Maurer MS, Fosbol E, et al
     Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implications.
     Am Heart J. 2024 Nov 14:S0002-8703(24)00296-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
160. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
     Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.
     Am Heart J. 2024;277:1-10.
     PubMed     Abstract available
     
     
     
161. NAVAS-ACIEN A, Mark DB, Anstrom K, Lamas GA, et al
     Response to Tomoyuki Kawada: Blood and urine metal levels in patients with diabetes and cardiovascular disease.
     Am Heart J. 2024;277:143-144.
     PubMed    
     
     
     
162. KAWADA T
     Blood and urine metal levels in patients with diabetes and cardiovascular disease.
     Am Heart J. 2024;277:142.
     PubMed    
     
     
     October 2024
163. BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al
     Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.
     Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
164. SHAH NP, Mulder H, Lydon B, Chiswell K, et al
     Real-World Exploration of LDL-Cholesterol Management in Patients with Atherosclerotic Cardiovascular Disease.
     Am Heart J. 2024 Oct 16:S0002-8703(24)00271-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
165. LUSK JB, Glover L, Soneji S, Granger CB, et al
     Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
     Am Heart J. 2024;276:110-114.
     PubMed     Abstract available
     
     
     September 2024
166. VOLPP KG, Mahraj K, Norton LA, Asch DA, et al
     Design and Rationale of Penn Medicine Healthy Heart, a Randomized Trial of Effectiveness of a Centrally Organized Approach to Blood Pressure and Cholesterol Improvement Among Patients at Elevated Risk of Atherosclerotic Cardiovascular Disease.
     Am Heart J. 2024 Sep 26:S0002-8703(24)00262-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
167. KODAIRA M, Hasan MS, Grossman Y, Guerrero C, et al
     Risk of Cardiovascular Events after Influenza Infection-related Hospitalizations in Adults with Congenital Heart Disease -A Nationwide Population Based Study.
     Am Heart J. 2024 Sep 4:S0002-8703(24)00226-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
168. NELSON MD, Gomez-Arnold JM, Wei J, Lauzon M, et al
     Contributors to high left ventricular ejection fraction in women with ischemia and no obstructive coronary artery disease: Results from the Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction (WISE-CVD) Study.
     Am Heart J. 2024 Sep 2:S0002-8703(24)00224-2. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
169. DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al
     Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
     Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     August 2024
170. HAMID H, Bagheri M, Benzing T, Krishnan S, et al
     Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and plaque.
     Am Heart J. 2024 Aug 24:S0002-8703(24)00218-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
171. JIANG C, Wang Z, Du X, Wang Y, et al
     Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: rationale and design of the CRAFT trial.
     Am Heart J. 2024 Aug 23:S0002-8703(24)00203-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
172. BROWN TM
     Cholesterol Lowering Therapy is Highly Efficacious in Reducing Atherosclerotic Cardiovascular Disease Risk but Grossly Underutilized: How do we Move the Needle?
     Am Heart J. 2024 Aug 16:S0002-8703(24)00201-1. doi: 10.1016/j.ahj.2024.
     PubMed    
     
     
     
173. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
     Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
     Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
174. AIHARA K, Torii S, Nakamura N, Hozumi H, et al
     Pathological Evaluation of Predictors for Delayed Endothelial Coverage After Currently Available Drug-eluting Stent Implantation in Coronary Arteries: Impact of Lesions With Acute and Chronic Coronary Syndromes.
     Am Heart J. 2024 Aug 7:S0002-8703(24)00197-2. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
175. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
     A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
     Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
176. VOGEL B, Jou S, Sartori S, Farhan S, et al
     Impact of sex on outcomes associated with polyvascular disease in patients after PCI.
     Am Heart J. 2024 Aug 7:S0002-8703(24)00196-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     July 2024
177. ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al
     Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease.
     Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
178. SINGH K, Nikhare K, Gandral M, Aithal K, et al
     Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial.
     Am Heart J. 2024 Jul 19:S0002-8703(24)00174-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
179. VERGHESE D, Hamal S, Ghanem A, Kinninger A, et al
     Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients with STable CoROnary Artery Disease CoMpared to Placebo (EKSTROM) Trial - Rationale and Design.
     Am Heart J. 2024 Jul 17:S0002-8703(24)00171-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     June 2024
180. JEYAPRAKASH P, Pathan F, Ozawa K, Robledo KP, et al
     Restoring microvascular circulation with diagnostic ultrasound and contrast agent: Rationale and Design of the REDUCE trial.
     Am Heart J. 2024 Jun 27:S0002-8703(24)00162-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
181. WU ZM, Kan J, Ye F, You W, et al
     PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study.
     Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
182. D'ENTREMONT MA, Lee SF, Mian R, Kedev S, et al
     Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction.
     Am Heart J. 2024 Jun 25:S0002-8703(24)00161-3. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
183. RAMASESHAN R, Perera D, Reid A, Andiapen M, et al
     REGENERATE-COBRA: A Phase II randomized sham-controlled trial assessing the safety and efficacy of intracoronary administration of autologous bone marrow-derived cells in patients with refractory angina.
     Am Heart J. 2024 Jun 9:S0002-8703(24)00146-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
184. SONG L, Guan C, Yu M, Sun Z, et al
     Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium everolimus-eluting stents in patients with coronary artery disease: rationale and design of the IRONMAN-II trial.
     Am Heart J. 2024 Jun 3:S0002-8703(24)00140-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     May 2024
185. MOK Y, Lu Y, Ballew SH, Sang Y, et al
     Premorbid physical activity and prognosis after incident myocardial infarction: the Atherosclerosis Risk in Communities Study.
     Am Heart J. 2024 May 7:S0002-8703(24)00120-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
186. KIM Y, Park H, Yoon HJ, Suh J, et al
     Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a Randomized Controlled Non-Inferiority Trial.
     Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
187. ZHANG F, Tian M, Wang X, Zhang H, et al
     Rationale and design of a Single-center Randomized Trial to Compare the Graft Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary Artery Bypass Grafting Surgery (GRAFT-CAB Study).
     Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
188. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
     Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN.
     Am Heart J. 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
189. COOPER JG, Ferguson J, Donaldson LA, Black KMM, et al
     Could paramedics use the HEART Pathway to identify patients at low-risk of myocardial infarction in the prehospital setting?
     Am Heart J. 2024;271:182-187.
     PubMed     Abstract available
     
     
     April 2024
190. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
     A Randomized Clinical Trial of Catheter Ablation and Antiarrhythmic Drug Therapy for Suppression of Ventricular Tachycardia in Ischemic Cardiomyopathy: The VANISH2 Trial.
     Am Heart J. 2024 Apr 20:S0002-8703(24)00096-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
191. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
     Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial.
     Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
192. DAUBERT MA, Stebbins A, Peragallo-Urrutia R, Chiswell K, et al
     Early Postpartum Blood Pressure Screening is Associated with Increased Detection of Cardiovascular Risk Factors in Women with Hypertensive Disorders of Pregnancy.
     Am Heart J. 2024 Apr 4:S0002-8703(24)00076-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
193. PARK DY, Jamil Y, Babapour G, Kim J, et al
     Association of Cardiovascular Diseases with Cognitive Performance in Older Adults.
     Am Heart J. 2024 Apr 2:S0002-8703(24)00077-2. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     March 2024
194. THOMAS A, Banna S, Shahu A, Ali T, et al
     Propofol vs etomidate for induction prior to invasive mechanical ventilation in patients with acute myocardial infarction.
     Am Heart J. 2024 Mar 28:S0002-8703(24)00074-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
195. WU Y, Hu L, Xie X, Li W, et al
     Different Dose Aspirin Plus Immunoglobulin (DAPI) for Prevention of Coronary Artery Abnormalities in Kawasaki Disease: Study Protocol for a Multi-centre, Prospective, Randomized, Open-label, Blinded End-point, Non-inferiority Trial.
     Am Heart J. 2024 Mar 18:S0002-8703(24)00071-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
196. KRUCOFF M, Spirito A, Baber U, Sartori S, et al
     Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.
     Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     February 2024
197. MEHDIPOOR G, Redfors B, Chen S, Gkargkoulas F, et al
     Hypertension, Microvascular Obstruction and Infarct Size in Patients with STEMI Undergoing PCI: Pooled Analysis from 7 Cardiac Magnetic Resonance Imaging Studies.
     Am Heart J. 2024 Feb 29:S0002-8703(24)00050-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
198. ZIEGELSTEIN RC, Kronish IM, Thombs BD
     Depression Screening to Improve Clinical Outcomes in Coronary Heart Disease Patients.
     Am Heart J. 2024 Feb 22:S0002-8703(24)00044-9. doi: 10.1016/j.ahj.2024.
     PubMed    
     
     
     
199. LEE SH, Lee SJ, Heo JH, Ahn SG, et al
     Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial.
     Am Heart J. 2024 Feb 22:S0002-8703(24)00041-3. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
200. DEHGHANI P, Singh J, Mancini GBJ, Stanberry L, et al
     Angiographic characteristics of Patients with STEMI and COVID-19 - Insights from NACMI Registry.
     Am Heart J. 2024 Feb 21:S0002-8703(24)00039-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     January 2024
201. ALVIAR CL, Li BK, Keller NM, Bohula-May E, et al
     Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry.
     Am Heart J. 2024 Jan 6:S0002-8703(23)00361-7. doi: 10.1016/j.ahj.2023.
     PubMed     Abstract available
     
     
     November 2023
202. MUNHOZ D, Collet C, Mizukami T, Yong A, et al
     Rationale and design of the pullback pressure gradient (PPG) global registry.
     Am Heart J. 2023;265:170-179.
     PubMed     Abstract available
     
     
     
203. DELMAS C, Laine M, Schurtz G, Roubille F, et al
     Rationale and design of the ULYSS trial: A randomized multicenter evaluation of the efficacy of early Impella CP implantation in acute coronary syndrome complicated by cardiogenic shock.
     Am Heart J. 2023;265:203-212.
     PubMed     Abstract available
     
     
     
204. DING Y, Li Q, Chen Q, Tang Y, et al
     Diagnostic performance of a novel automated CT-derived FFR technology in detecting hemodynamically significant coronary artery stenoses: A multicenter trial in China.
     Am Heart J. 2023;265:180-190.
     PubMed     Abstract available
     
     
     September 2023
205. WENG Z, Zhao C, Qin Y, Liu C, et al
     Peripheral atherosclerosis in acute coronary syndrome patients with plaque rupture vs plaque erosion: A prospective coronary optical coherence tomography and peripheral ultrasound study.
     Am Heart J. 2023;263:159-168.
     PubMed     Abstract available
     
     
     
206. ATALLAH J, Chiha T, Chen C, Siller-Matula JM, et al
     Clinical outcomes associated with type II myocardial infarction caused by bleeding.
     Am Heart J. 2023;263:85-92.
     PubMed     Abstract available
     
     
     
207. ANANTH CV, Rutherford C, Rosenfeld EB, Brandt JS, et al
     Epidemiologic trends and risk factors associated with the decline in mortality from coronary heart disease in the United States, 1990-2019.
     Am Heart J. 2023;263:46-55.
     PubMed     Abstract available
     
     
     July 2023
208. PARK S, Rha SW, Choi BG, Kim W, et al
     Efficacy and Safety of Cilostazol-Based Triple Antiplatelet Therapy Compared with Clopidogrel-Based Dual Antiplatelet Therapy in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter, Rando
     Am Heart J. 2023 Jul 3:S0002-8703(23)00172-2. doi: 10.1016/j.ahj.2023.
     PubMed     Abstract available
     
     
     June 2023
209. LI C, Eikelboom JW, Zhong Z, Zhang X, et al
     Efficacy and safety of a bolus of half-dose r-SAK prior to primary PCI in ST-elevation myocardial infarction: Rationale and design of the OPTIMA-6 trial.
     Am Heart J. 2023 Jun 25:S0002-8703(23)00168-0. doi: 10.1016/j.ahj.2023.
     PubMed     Abstract available
     
     
     May 2023
210. SHAH NP, Peterson ED, Page C, Blanco R, et al
     Generalizability of an EHR-Network Dataset to the United States for Cardiovascular Disease Conditions: Comparison of Cerner Real World Data with the National Inpatient Sample.
     Am Heart J. 2023 May 15:S0002-8703(23)00120-5. doi: 10.1016/j.ahj.2023.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum